Blog
RSS FeedPosted by Michael Wonder on 08 Aug 2022
Funding for lifesaving drug denied by B.C. health authority as couple struggles to fund their portion
7 August 2022 - Entrectinib, a targeted drug that had shown positive results in tumours that had the same gene expression, ...
Posted by Michael Wonder on 30 Jul 2022
Amylyx Pharmaceuticals announces Albrioza is now available in Canada for the treatment of amyotrophic lateral sclerosis
29 July 2022 - Amylyx Pharmaceuticals today announced that Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) is now commercially available in Canada for ...
Posted by Michael Wonder on 25 Jul 2022
HLS announces that Vascepa is now reimbursed by Ontario's Provincial Drug Plan
25 July 2022 - Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private ...
Posted by Michael Wonder on 21 Jul 2022
Pfizer announces Prevnar 20 (pneumococcal 20 valent conjugate vaccine) is now available in Canada for the prevention of pneumonia and invasive pneumococcal disease in adults 18 years of age and older
21 July 2022 - Prevnar 20 is the first conjugate vaccine indicated to help protect against 20 serotypes responsible for ...
Posted by Michael Wonder on 21 Jul 2022
Health Canada approves AbbVie's Rinvoq (upadacitinib) for the treatment of adults with active ankylosing spondylitis
20 July 2022 - Approval is supported by efficacy and safety data of two pivotal studies in which Rinvoq demonstrated improvements ...
Posted by Michael Wonder on 18 Jul 2022
More children now eligible for cystic fibrosis drug
18 July 2022 - Effective today, the Province will pay for the cystic fibrosis drug Trikafta for children aged six to ...
Posted by Michael Wonder on 15 Jul 2022
Health Canada authorises use of Moderna COVID-19 vaccine in children 6 months to 5 years of age
14 July 2022 - Today, Health Canada authorised the use of the Moderna Spikevax COVID-19 vaccine in children 6 months to ...
Posted by Michael Wonder on 13 Jul 2022
Canada making progress in prescription drug coverage
13 July 2022 - Canada has seen a significant improvement in the number of Canadians eligible for some form of prescription ...
Posted by Michael Wonder on 12 Jul 2022
Alberta expands access to cystic fibrosis drug Trikafta for children 6 to 11
11 July 2022 - Children with cystic fibrosis can now live 'longer, healthier and fuller lives,' says advocate. ...
Posted by Michael Wonder on 11 Jul 2022
CADTH Advisory Panel report recommends framework for potential pan-Canadian formulary
11 July 2022 - In July 2021, the Government of Canada approached CADTH to develop a recommended framework for creating and ...
Posted by Michael Wonder on 11 Jul 2022
Arcutis Biotherapeutics announces Health Canada accepts for review the new drug submission for roflumilast cream for adults and adolescents with plaque psoriasis
11 July 2022 - Submission supported by positive clinical data from the pivotal Phase 3 DERMIS-1 and DERMIS-2 clinical studies, as ...
Posted by Michael Wonder on 07 Jul 2022
Vertex announces letter of intent with the pan-Canadian Pharmaceutical Alliance for public reimbursement of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 6 and older
7 July 2022 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical ...
Posted by Michael Wonder on 06 Jul 2022
Regulatory submission for GSK's daprodustat accepted into Health Canada review
6 July 2022 - Canadian regulatory submission acceptance follows that of the US FDA and the EMA as well as ...
Posted by Michael Wonder on 06 Jul 2022
Health Canada approves HyQvia, a new treatment for Canadians with immune deficiencies
6 July 2022 - New immunoglobulin treatment offers Canadian patients option of subcutaneous once-monthly (every three or four weeks) dosing. ...
Posted by Michael Wonder on 05 Jul 2022
Sandoz Canada expands its generics portfolio with three new products
5 July 2022 - Generic medicines like these three products help make effective medicine more affordable and accessible for Canadians and ...